Study Assessing the PK of EFB0027 and Effect on Circulating Glucose and GI Hormone Concentrations in Subjects With T2DM
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study will evaluate how EFB0027 and EFB0026 behave in subjects with type 2 diabetes mellitus.
In addition, this study will compare the effects of EFB0027 and EFB0026 on circulating concentrations of glucose and gastrointestinal hormones in subjects with type 2 diabetes mellitus.
| Condition | Intervention | Phase |
|---|---|---|
|
Type 2 Diabetes Mellitus |
Drug: EFB0027 Drug: EFB0026 |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Pharmacokinetics Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Basic Science |
- Concentration of EFB0026 and EFB0027, measured in ng/mL [ Time Frame: -5, 15, 30, 60, 90, 120, 150, 180, 240, 360, 480,600, and 660 min relative to the start time of the standardized breakfast at Visits 3, 5, 7, and 9 ] [ Designated as safety issue: No ]
| Enrollment: | 24 |
| Study Start Date: | May 2012 |
| Estimated Study Completion Date: | March 2013 |
| Estimated Primary Completion Date: | March 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1000 mg EFB0026
BID
|
Drug: EFB0026
Active comparator
|
|
Experimental: 1000 mg EFB0027
BID
|
Drug: EFB0027
Comparison of enteric-coating to assess effect on PK
|
|
Experimental: 500 mg EFB0027
BID
|
Drug: EFB0027
Comparison of enteric-coating to assess effect on PK
|
|
Experimental: 500 mg EFB0026 + 1000 mg EFB0027
BID
|
Drug: EFB0027
Comparison of enteric-coating to assess effect on PK
Drug: EFB0026
Active comparator
|
Eligibility| Ages Eligible for Study: | 19 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Is 19 to 70 (inclusive) years old at Visit 1 (Screening).
Is diagnosed with Type 2 Diabetes Mellitus with
HbA1c between 6.0 to 9.5% (inclusive) for subjects managing their diabetes with:
i. Diet and exercise alone, or ii. A stable regimen (minimum of 2 months at Visit 1) of metformin alone, or iii. A stable regimen (minimum of 2 months at Visit 1) of DPP-4 inhibitor alone, OR
- HbA1c between 6.0 to 8.5% (inclusive) for subjects managing their diabetes with a stable (minimum of 2 months at Visit 1) combination regimen of metformin and DPP-4 inhibitors.
- Has serum creatinine below the upper limit of normal at Visit 1 and an estimated creatinine clearance above 80 using the Crockroft and Gault equation (CrCl = [(140 - age) x body weight in kg] / (serum creatinine x 72) x (0.85 for females) [ref. 3].
- Has a body mass index (BMI) of 25.0 to 40.0 kg/m2 (inclusive) at Screening.
Is male, or is female and meets all of the following criteria:
- Not breastfeeding
- Negative pregnancy test result (human chorionic gonadotropin, beta subunit) at Visit 1 (Screening) (not applicable to hysterectomized females)
- Surgically sterile, postmenopausal, or if of childbearing potential, must practice and be willing to continue to practice appropriate birth control during the entire duration of the study
- Has a physical examination with no clinically significant abnormalities as judged by the investigator.
- Ability to understand and willingness to adhere to protocol requirements.
- If on chronic thyroid pharmacologic therapy, the dose must be stable for at least 3 months prior to Visit 1 (Screening), and must have thyroid-stimulating hormone (TSH) test result in normal range at Visit 1 (Screening).
Exclusion Criteria:
Has a clinically significant medical condition that could potentially affect study participation and/or personal well-being, as judged by the investigator, including but not limited to the following conditions:
- Hepatic disease
- Renal disease
- Gastrointestinal disease
- Endocrine disorder except diabetes
- Cardiovascular disease
- Seizure disorder
- Organ transplantation
- Chronic infection
- Has any chronic disease requiring medication that has been adjusted in the past 90 days (subjects may take acute intermittent over-the-counter medications such as Tylenol, if needed).
- Has any drug treatment that affects gastric pH (prescription or over-the-counter), including any antacids or medications such as Rolaids or Pepcid within 2 days of Visit 1 (Screening).
- Has had major surgery of any kind within 6 months of Visit 1 (Screening).
- Has received a blood transfusion within 6 months of Visit 1 (Screening).
- Has a history of >5 kg weight change within 3 months of Visit 1 (Screening).
- Has clinical laboratory test (clinical chemistry, hematology, or urinalysis) abnormalities other than those expected in subjects with diabetes and judged by the investigator to be clinically significant at Visit 1 (Screening).
- Has physical, psychological, or historical finding that, in the investigator's opinion, would make the subject unsuitable for the study.
- Currently abuses drugs or alcohol or has a history of abuse that in the investigator's opinion would cause the individual to be noncompliant with study procedures.
- Has donated blood within 2 months of Visit 1 (Screening) or is planning to donate blood during the study.
- Has used insulin within 3 months of Visit 1 (Screening).
- Has received GLP-1 receptor agonists and/or thiazolidinedione treatment within 6 months of Visit 1 (Screening).
- Has known intolerance to metformin.
- Has received any investigational drug within 1 month (or five half-lives of the investigational drug, whichever is greater) of Visit 1 (Screening).
- Has known allergies or hypersensitivity to any component of study treatment.
- Is employed by Elcelyx Therapeutics, Inc (that is an employee, temporary contract worker, or designee of the company).
- Smokes more than 10 cigarettes per day, 2 cigars per day, or uses more than 1 can of smokeless tobacco per week.
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Elcelyx Therapeutics, Inc. |
| ClinicalTrials.gov Identifier: | NCT01677299 History of Changes |
| Other Study ID Numbers: | LCPOC10 |
| Study First Received: | August 23, 2012 |
| Last Updated: | March 28, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
ClinicalTrials.gov processed this record on May 19, 2013